Despite solid returns on prior investments in biomedical firms, investors seem disinclined to finance new startups this year, Luke Timmerman writes. The number of first-time financings for life sciences companies through the first three quarters of 2013 was the lowest since 1996, according to data from Thomson Reuters. The number of active venture capital firms has declined over the last five years, and many big institutional investors do not believe that the rewards in life sciences investing justify the risks.

Full Story:

Related Summaries